| Primary |
| Gout |
37.1% |
| Product Used For Unknown Indication |
17.4% |
| Hypertension |
14.3% |
| Familial Mediterranean Fever |
6.7% |
| Blood Cholesterol Increased |
3.7% |
| Diabetes Mellitus |
3.7% |
| Pericarditis |
1.9% |
| Hypothyroidism |
1.8% |
| Vitamin Supplementation |
1.5% |
| Anticoagulant Therapy |
1.3% |
| Prophylaxis |
1.3% |
| Arthritis |
1.2% |
| Cardiovascular Event Prophylaxis |
1.2% |
| Gastrooesophageal Reflux Disease |
1.2% |
| Atrial Fibrillation |
1.1% |
| Chondrocalcinosis Pyrophosphate |
1.1% |
| Anxiety |
0.9% |
| Asthma |
0.9% |
| Back Pain |
0.9% |
| Pain |
0.9% |
|
| Drug Ineffective |
24.9% |
| Diarrhoea |
22.9% |
| Product Substitution Issue |
4.5% |
| Drug Effect Decreased |
4.1% |
| Hypoaesthesia |
4.1% |
| Nausea |
4.1% |
| Rash |
4.1% |
| Myalgia |
3.7% |
| Off Label Use |
3.7% |
| Dizziness |
3.3% |
| Vomiting |
3.3% |
| Weight Decreased |
3.3% |
| Renal Failure Acute |
2.4% |
| Death |
2.0% |
| Abdominal Pain Upper |
1.6% |
| Drug Interaction |
1.6% |
| Fatigue |
1.6% |
| Headache |
1.6% |
| Maternal Drugs Affecting Foetus |
1.6% |
| Pollakiuria |
1.6% |
|
| Secondary |
| Gout |
35.6% |
| Hypertension |
17.6% |
| Product Used For Unknown Indication |
10.8% |
| Blood Cholesterol Increased |
3.9% |
| Blood Pressure Increased |
3.3% |
| Anticoagulant Therapy |
2.9% |
| Pericarditis |
2.9% |
| Angina Pectoris |
2.6% |
| Familial Mediterranean Fever |
2.3% |
| Pain |
2.3% |
| Hormone Replacement Therapy |
2.0% |
| Hypothyroidism |
2.0% |
| Atrial Fibrillation |
1.6% |
| Blood Cholesterol |
1.6% |
| Diabetes Mellitus |
1.6% |
| Hyperuricaemia |
1.6% |
| Prophylaxis |
1.6% |
| Stent Placement |
1.6% |
| Anaemia |
1.0% |
| Arthritis |
1.0% |
|
| Diarrhoea |
22.4% |
| Drug Ineffective |
20.7% |
| Off Label Use |
8.6% |
| Eyelid Oedema |
5.2% |
| Insomnia |
5.2% |
| Weight Decreased |
5.2% |
| Diarrhoea Haemorrhagic |
3.4% |
| Micturition Urgency |
3.4% |
| Nausea |
3.4% |
| Rash Pruritic |
3.4% |
| Vomiting |
3.4% |
| Abdominal Discomfort |
1.7% |
| Back Pain |
1.7% |
| Blood Creatinine Increased |
1.7% |
| Blood Pressure Increased |
1.7% |
| Cardiac Failure Congestive |
1.7% |
| Death |
1.7% |
| Diabetes Mellitus |
1.7% |
| Drug Effect Decreased |
1.7% |
| Drug Effect Delayed |
1.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
34.2% |
| Gout |
15.1% |
| Premedication |
7.3% |
| Hypertension |
6.3% |
| Pain |
4.6% |
| Arthritis |
3.3% |
| Drug Use For Unknown Indication |
3.3% |
| Crohn's Disease |
2.9% |
| Diabetes Mellitus |
2.8% |
| Allergy Prophylaxis |
2.7% |
| Gastrooesophageal Reflux Disease |
2.7% |
| Rheumatoid Arthritis |
2.6% |
| Cardiac Disorder |
1.8% |
| Atrial Fibrillation |
1.8% |
| Asthma |
1.6% |
| Blood Cholesterol Increased |
1.6% |
| Chronic Obstructive Pulmonary Disease |
1.4% |
| Neuropathy Peripheral |
1.4% |
| Depression |
1.3% |
| Hepatitis C |
1.1% |
|
| Therapeutic Response Decreased |
11.1% |
| Infusion Related Reaction |
7.8% |
| Death |
6.7% |
| Injection Site Pain |
6.7% |
| Drug Ineffective |
5.6% |
| Gout |
5.6% |
| Pain |
5.6% |
| Weight Increased |
5.6% |
| Headache |
4.4% |
| Nausea |
4.4% |
| Off Label Use |
4.4% |
| Renal Failure |
4.4% |
| Urticaria |
4.4% |
| Diarrhoea |
3.3% |
| Fatigue |
3.3% |
| Inappropriate Schedule Of Drug Administration |
3.3% |
| Renal Disorder |
3.3% |
| Sinusitis |
3.3% |
| Vertigo |
3.3% |
| Vomiting |
3.3% |
|
| Interacting |
| Asthma |
20.0% |
| Blood Cholesterol Increased |
20.0% |
| Chondrocalcinosis Pyrophosphate |
20.0% |
| Inflammation |
20.0% |
| Pain |
20.0% |
|
|
